Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $47.00 price target on the stock. Separately, Piper Sandler reiterated an overweight rating and issued a $8.00 price objective on shares of Tempest Therapeutics […]
More Stories
Mather Group LLC. Sells 1,153 Shares of Canadian National Railway (NYSE:CNI)
Mather Group LLC. reduced its stake in Canadian National Railway (NYSE:CNI – Free Report) (TSE:CNR) by 21.3% during the 3rd...
Brokerages Set KKR & Co. Inc. (NYSE:KKR) PT at $132.64
KKR & Co. Inc. (NYSE:KKR – Get Free Report) has received a consensus rating of “Buy” from the sixteen ratings...
DIMO (DIMO) Self Reported Market Cap Achieves $11.88 Million
DIMO (DIMO) traded up 3.3% against the dollar during the 1 day period ending at 11:00 AM E.T. on October...
MSCI Inc. (NYSE:MSCI) Shares Bought by Mather Group LLC.
Mather Group LLC. lifted its position in MSCI Inc. (NYSE:MSCI – Free Report) by 5.7% in the 3rd quarter, according...
Dynamic Advisor Solutions LLC Trims Stake in The Trade Desk, Inc. (NASDAQ:TTD)
Dynamic Advisor Solutions LLC reduced its position in The Trade Desk, Inc. (NASDAQ:TTD – Free Report) by 0.7% during the...
Atomi Financial Group Inc. Increases Position in Pool Co. (NASDAQ:POOL)
Atomi Financial Group Inc. raised its position in shares of Pool Co. (NASDAQ:POOL – Free Report) by 8.2% during the...